Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01996306
Other study ID # AXEPT
Secondary ID UMIN000012263
Status Completed
Phase Phase 3
First received
Last updated
Start date December 2, 2013
Est. completion date June 30, 2018

Study information

Verified date January 2019
Source Epidemiological and Clinical Research Information Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to determine the non-inferiority of overall survival XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.


Description:

Primary endpoint: Overall survival (OS), Secondary endpoints: Progression-free survival (PFS), Time to treatment failure (TTF), Overall response rate (ORR),Disease Control Rate (DCR), Relative dose intensity, Safety, and Correlation between UGT1A1 genotype and Safety.


Recruitment information / eligibility

Status Completed
Enrollment 650
Est. completion date June 30, 2018
Est. primary completion date November 20, 2017
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Histologically-confirmed inoperable colorectal adenocarcinoma excluding vermiform appendix cancer and anal canal cancer.

2. Age =20 years at the time of informed consent

3. ECOG performance status (PS) of 0-2

4. Written informed consent prior to study-specific screening procedures

5. Life expectancy of at least 90 days

6. Withdrawal from first-line chemotherapy (regardless of containing molecular-targeted drugs) for metastatic colorectal cancer due to intolerable toxicity or progressive disease, or relapse within 180 days after the last dose of adjuvant chemotherapy.

7. Adequate organ function according to following laboratory values obtained within 14 days before enrolment (excluding patients who received blood transfusions or hematopoietic growth factors within 14 days before the laboratory test) Neutrophil count: =1500/mm3 Platelet count: =10.0 x 104/mm3 Hemoglobin: =9.0 g/dL Total bilirubin: =1.5 mg/dL AST, ALT: =100 IU/L (=200 IU/I if liver metastases present) Serum creatinine: =1.5 mg/dL

Exclusion Criteria:

1. History of other malignancy with a disease-free interval <5 years (other than curatively treated cutaneous basal cell carcinoma, curatively treated carcinoma in situ of the cervix, and gastroenterological cancer confirmed to be cured by endoscopic mucosal resection)

2. With massive pleural effusion or ascites requiring intervention

3. Radiological evidence of brain tumor or brain metastases

4. Active infection including hepatitis

5. Any of the following complication:

i) Gastrointestinal bleeding or gastrointestinal obstruction (including paralytic ileus) ii) Symptomatic heart disease (including unstable angina, myocardial infarction, and heart failure) iii) Interstitial pneumonia or pulmonary fibrosis iv) Uncontrolled diabetes mellitus v) Uncontrolled diarrhea (that interferes with daily activities despite adequate therapy)

6. Any of the following medical history:

Myocardial infarction: History of one episode within one year before enrollment or two or more lifetime episodes i) Serious hypersensitivity to any of the study drugs ii) History of adverse reaction to fluoropyrimidines suggesting dihydropyrimidine dehydrogenase (DPD) deficiency

7. Previous treatment with irinotecan hydrochloride

8. Current treatment with atazanavir sulfate

9. Previous treatment with tegafur, gimeracil, and oteracil potassium within seven days before enrollment

10. Pregnant or lactating females, and males and females unwilling to use contraception

11. Requires continuous treatment with systemic steroids

12. Psychiatric disability that would preclude study compliance

13. Otherwise determined by the investigator to be unsuitable for participation in the study

14. Concurrent gastrointestinal perforation or history of gastrointestinal perforation with 1 year before enrollment

15. History of pulmonary hemorrhage/hemoptysis = Grade 2 (defined as bright red blood of at least 2.5mL) within 1 month prior to enrollment.

16. History of laparotomy, thoracotomy, or intestinal resection within 28 days before enrollment

17. Unhealed wound (except suture wounds from implantation of a central venous port), gastrointestinal ulcer, or traumatic fracture

18. Current or recent (within 1 year) thromboembolism or cerebrovascular disease

19. Currently receiving or requires anticoagulation therapy (> 325 mg/day of aspirin)

20. Bleeding diathesis, coagulopathy, or coagulation factor abnormality (INR =1.5 within 14 days before enrollment)

21. Uncontrolled hypertension

22. Urine dipstick for proteinuria >+2

Study Design


Intervention

Biological:
Bevacizumab
5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
Drug:
CPT-11 (Irinotecan)
150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
5-FU Bolus
400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
5-FU Infusion
2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
l-LV (dl-LV)
200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
Biological:
bevacizumab
7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
Drug:
CPT-11 (Irinotecan)
150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
Capecitabine
1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.

Locations

Country Name City State
Japan NPO Epidemiological and Clinical Research Information Network (ECRIN) Kyoto

Sponsors (1)

Lead Sponsor Collaborator
Epidemiological and Clinical Research Information Network

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival Time from the date of enrollment to death from any cause. Assessed until 1.5 years after the last patient enrolment
Secondary Progression-free survival (PFS) Time from the date of enrollment to the earlier of the date of confirmed progression or death from any cause. Assessed until 1.5 years after the last patient enrolment
Secondary Time to treatment failure (TTF) Time from the date of enrollment to the earlier of the date of confirmed progression, death from any cause, or discontinuation of protocol treatment. Assessed until 1.5 years after the last patient enrolment
Secondary Overall Response Rate (ORR) Proportion of eligible patients with measurable lesions with a best overall response of CR or PR assessed by the attending physician. Assessed at 6, 12 week and thereafter every 8 weeks
Secondary Disease Control Rate (DCR) Proportion of best overall response of CR, PR, or SD assessed by the attending physician. Assessed at 6, 12 week and thereafter every 8 weeks
Secondary Relative Dose Intensity will be calculated for each drug to evaluate treatment compliance in the all-treated population during the observation period. Assessed until final dosing to the last patient
Secondary Incidence of Adverse Events (Adverse Reactions) The incidence of worst-grade adverse events (toxicities) on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm in all treated patients for the following events. Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery
Secondary Correlation between UGT1A1 genotype and safety The incidence of worst-grade adverse events on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm and UGT1A1 genotype in all treated patients with a known UGT1A1 genotype profile Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery
See also
  Status Clinical Trial Phase
Recruiting NCT04552093 - Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT) Phase 2/Phase 3
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Recruiting NCT03561350 - Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
Recruiting NCT06128798 - Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Completed NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Phase 2
Withdrawn NCT04192929 - Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02889679 - Underwater Resection of Non-pedunculated Colorectal Lesions N/A
Terminated NCT02842580 - De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02564835 - Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer N/A
Completed NCT02149108 - Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) Phase 3
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02599103 - The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects N/A
Completed NCT01669109 - Hatha Yoga for Patients With Colorectal Cancer N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Recruiting NCT01428752 - Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer N/A
Completed NCT01978717 - General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer N/A
Completed NCT01877018 - Colorectal Cancer Screening in Primary Care N/A